(Q33387755)

English

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Athanasios Dimopoulos

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Dimitrios Bafaloukos

1

object named as

Dimitrios Bafaloukos

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Dimitrios Pectasides

15

object named as

Dimitrios Pectasides

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Pavlos Papakostas

14

object named as

Pavlos Papakostas

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Helena Linardou

2

object named as

Helena Linardou

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Gerasimos Aravantinos

3

object named as

Gerasimos Aravantinos

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Aristotelis Bamias

5

object named as

Aristotelis Bamias

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Eleni Timotheadou

9

object named as

Eleni Timotheadou

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Thomas Makatsoris

10

object named as

Thomas Makatsoris

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Epaminondas Samantas

11

object named as

Epaminondas Samantas

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Evangelos Briasoulis

12

object named as

Evangelos Briasoulis

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Christos Christodoulou

13

object named as

Christos Christodoulou

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Christos Papadimitriou

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Paris Kosmidis

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

George Fountzilas

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

0 references

publication date

7 January 2010

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2823653

21 June 2018

Are there circumstances in which phase 2 study results should be practice-changing?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2823653

21 June 2018

Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwe

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2823653

21 June 2018

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (A

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2823653

21 June 2018

Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2823653

21 June 2018

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2823653

21 June 2018

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2823653

21 June 2018

Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2823653

21 June 2018

Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2823653

21 June 2018

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2823653

21 June 2018

Relapsed ovarian cancer: challenges and management strategies for a chronic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2823653

21 June 2018

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2823653

21 June 2018

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-8-3

21 January 2018

Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-8-3

21 January 2018

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-8-3

21 January 2018

Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-8-3

21 January 2018

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-8-3

21 January 2018

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-8-3

21 January 2018

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-8-3

21 January 2018

CONSORT: An Evolving Tool to Help Improve the Quality of Reports of Randomized Controlled Trials

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-8-3

21 January 2018

Use of tumour markers in monitoring the course of ovarian cancer

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-8-3

21 January 2018

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design

1 reference

https://pubmed.ncbi.nlm.nih.gov/20055981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]

1 reference

https://pubmed.ncbi.nlm.nih.gov/20055981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of epithelial ovarian carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20055981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20055981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1741-7015-8-3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20055981%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33387755&oldid=2195311849"